Emrock Corporation Q2 FY27 Results (BSE: 531676)
Signal: Steady quarter
The read
The key inflection is the emergence of pharma as a ₹242.37 lakh revenue and ₹142.17 lakh result segment alongside solar's ₹23.47 lakh result, lifting consolidated PAT to ₹177.77 lakh from ₹24.57 lakh YoY; however, EPS growth of 138.3% materially lagged PAT growth of 623.2% because the share base expanded.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹3.03 Cr | +510.9% | +367.5% |
| Net profit | ₹1.78 Cr | +623.2% | |
| EPS | ₹1.12 | +138.3% | |
| EBIT margin | N/A |
P&L walk
Consolidated revenue rose to ₹303.06 lakh from ₹49.61 lakh YoY and ₹64.83 lakh QoQ, while PAT increased to ₹177.77 lakh from ₹24.57 lakh YoY and ₹19.01 lakh QoQ; the reported uplift is concentrated in pharma and solar segment results.
Segments
Pharma was the primary driver with ₹242.37 lakh of revenue and ₹142.17 lakh of segment result, while solar added ₹40.01 lakh of revenue and ₹23.47 lakh of result; real estate and hospitality contributed no current-quarter revenue or result.
Key positives
- Pharma contributed ₹242.37 lakh of revenue and ₹142.17 lakh of segment result in Q2FY27, becoming the largest disclosed earnings contributor.
- Solar segment revenue rose to ₹40.01 lakh, +33.4% YoY, while solar result rose to ₹23.47 lakh, +57.8% YoY.
- Consolidated PAT increased to ₹177.77 lakh from ₹24.57 lakh YoY and ₹19.01 lakh QoQ.
Key concerns
- EPS growth of 138.3% materially lagged PAT growth of 623.2% because paid-up equity capital was ₹1,582.00 lakh versus ₹522.00 lakh in the year-ago quarter.
- The current earnings mix is highly concentrated: pharma contributed ₹142.17 lakh of the ₹177.77 lakh consolidated PAT, while real estate and hospitality reported zero current-quarter segment revenue.
- Solar segment liabilities rose to ₹1,246.31 lakh from ₹5.25 lakh at March 2026, increasing balance-sheet execution risk around the expanded solar asset base.
Research and educational content only. Not investment advice.